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1. Introduction 
Pulmonary hypertension (PHT) is frequently seen in the critically ill patient. PHT is defined as 
a mean pulmonary arterial pressure (MPAP) >25mmHG at rest (Farber and Loscalzo, 2004; 
Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European 
Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the 
International Society of Heart and Lung Transplantation (ISHLT), 2009). The updated clinical 
classification (Dana Point 2008) describes pulmonary hypertension according to arterial or 
venous aetiology, as well as those associated with heart, respiratory and thromboembolic 
diseases (Table 1) (Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of 
the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), 
endorsed by the International Society of Heart and Lung Transplantation (ISHLT), 2009). 
PHT is inextricably linked to respiratory and right ventricular (RV) function. Increased 
pulmonary vascular resistance increases the afterload of the right ventricle, eventually 
leading to RV dysfunction and failure. This is reflected clinically as systemic venous 
hypertension with the classical signs of distended neck veins, pulsatile hepatomegaly and 
peripheral oedema. A vicious cycle is set up as elevated right ventricular end-diastolic 
pressures worsens tricuspid insufficiency, which in turn aggravates splanchnic and 
peripheral venous engorgement, leading to organ failure by reducing the perfusion pressure 
within these organs (Figure 1). Due to ventricular interdependence, left sided filling and 
contractility also becomes impaired, further contributing to systemic hypotension and organ 
hypoperfusion. It is therefore not surprising that the presence of PHT and RV failure is 
associated with a poorer clinical outcome in ICU patients (Moloney et al., 2003; Osman et al., 
2008; Ribiero et al., 1997; Viellard Baron et al., 2001).  
ICU patients are at particular risk for developing PHT and RV failure for a number of 
reasons. Firstly, the presence of mechanical ventilation may impose an additional load on 
the RV. Secondly, ARDS inevitably increases pulmonary vascular resistance due to the 
presence of pulmonary vasoconstriction, which in turn may be triggered by hypoxia and the 
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release of vasoconstrictive mediators. Thirdly, endothelial dysfunction and high risk for 
pulmonary vascular occlusion also contribute to increased pulmonary vascular resistance. It 
is estimated that approximately 25% of patients with ARDS have right ventricular 
dysfunction and pulmonary hypertension (Viellard Baron et al., 2001) . 
 
Table 1. Updated clinical classification of pulmonary hypertension (Dana Point 2008). 
Reprinted from the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension 
of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), 
endorsed by the International Society of Heart and Lung Transplantation (ISHLT), 2009 with 
permission from Oxford University Press. 
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Fig. 1. Increased pulmonary vascular pressures lead to right ventricular dysfunction, 
impaired left sided filling and contractility, systemic hypotension and organ hypoperfusion. 
Management of pulmonary hypertension in this group of patients is complex, given that the 
critically ill are often haemodynamically unstable, have varying responses to loading 
conditions on the heart, and are commonly mechanically ventilated. There is a complex 
interaction between the left and right ventricles, and management strategies that apply to 
non-ventilated inpatients or outpatients do not necessarily apply in the ICU setting. 
In this paper we review the pathophysiology, diagnostic possibilities and discuss 
management strategies of PHT in the critically ill. 
2. Pathophysiology 
The molecular pathophysiology of pulmonary hypertension is complex and probably varies 
depending on causative factors. In general however, pulmonary hypertension may be 
regarded as an imbalance between vasodilatory and vasoconstrictive forces leading to 
abnormal vascular reactivity in the pulmonary vascular bed predisposing to vasoconstriction. 
Several molecular mechanisms have been implicated in the pathogenesis of pulmonary 
hypertension and the reader is referred to Farber & Localzo, 2004 and Mandegar et al., 2004 for 
in-depth reviews. There are numerous experimental and clinical data demonstrating the 
importance of pulmonary vasocontrictors such as endothelin-1 (ET-1), serotonin, thromboxane 
and leukotrienes, acting against vasodilators such as adrenomedullin, nitric oxide (NO) and 
prostacyclin via second messengers such as cAMP and cGMP (Berkenbosch et al., 2000; Chew 
et al., 2008; Farber & Localzo, 2004; Giaid et al., 1993;  Giaid and Saleh, 1995; Moloney et al., 
2003; Steudel et al., 1997; Zhao et al., 2003). Neurohormonal factors such as atrial and brain 
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natriuretic peptides seem not only to be markers of disease severity, but play an active role by 
promoting cGMP mediated pulmonary vasodilation (Zhao et al., 2003). Hypoxic pulmonary 
vasoconstriction, a normally adaptive mechanism directing blood away from poorly ventilated 
areas may become maladaptive when sustained, contributing to increased pulmonary vascular 
resistance. At the cellular level, a number of mechanisms including potassium channel 
downregulation contribute to pathological intracellular calcium handling and homeostatis. The 
end result is smooth muscle proliferation, vascular remodelling and vasocontriction. Finally, 
genetic factors also play a role in the development of pulmonary hypertension. For example, an 
imbalance between apoptosis and proliferation is thought to occur as a result of mutations in 
bone morphogenetic receptor type II (BMP-R2) and polymorphisms in the serotonin receptor 
transporter (Mandegar et al., 2004; Newman et al., 2001) have been described. 
3. Diagnosis and haemodynamic monitoring of pulmonary hypertension  
3.1 Monitoring 
The definition of to monitor is ‘to watch over somebody or something, especially to ensure 
that good order or proper conduct is obtained’. The three components of monitoring are the 
subject matter, parameters measured, and periodicity chosen. Pulmonary hypertension 
being the subject matter leads to a number of parameters that should be considered for 
measurement including central venous pressure/right atrial pressure (CVP/RAP), 
pulmonary artery pressures (systolic, mean, diastolic), mixed venous oxygen saturation 
(Sv02), cardiac output (CO), right ventricular systolic function, and left ventricular end 
diastolic pressure or left atrial pressure (LAP). Periodicity will vary according to the clinical 
objectives, although in the critically ill patient parameters are likely to measured 
continuously, over hours or sometimes over days. 
Two modalities are available to the physician managing the critically ill patient with PHT 
are (1) right heart catherization using the pulmonary artery catheter and (2) echoDoppler 
(ED) assessment. 
3.1.1 Pulmonary Artery Catheter 
Right heart catheterization using the pulmonary artery catheter (PAC) is the gold standard 
in the confirming the diagnosis and accurately monitoring the haemodynamic abnormalities 
on a minute-to-minute basis in PHT. PAH is defined by a MPAP ≥25 mm Hg at rest and by a 
pulmonary vascular resistance (PVR) > 3 mm Hg/l (Wood units) (Task Force for the 
Diagnosis and Treatment of Pulmonary Hypertension of the European Society of 
Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the 
International Society of Heart and Lung Transplantation (ISHLT), 2009), with further 
subclassification into precapillary or postcapillary PHT determined by the pulmonary 
capillary wedge pressure (PCWP) and transpulmonary gradient ( TPG = MPAP – PCWP). In 
addition to the benefit of RHC in obtaining an accurate PAP measurement, it should be 
utilized where rapid assessment of responses to intravenous or nebulised therapy is 
required. Although the emphasis may be on the PAP, including the systolic (SPAP), mean 
(MPAP) and diastolic (DPAP) pulmonary arterial pressures, other parameters including 
cardiac output, pulmonary vascular resistance, mixed venous oxygen saturation and the 
PCWP may contribute to the evaluation. These should be measured in conjunction with 
systemic circulation parameters including arterial oxygen saturation and blood pressure. 
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Fig. 2. Increased intracellular calcium [Ca2+]cyt triggers pulmonary vasoconstriction and 
promotes pulmonary vascular remodeling via several mechanisms: 1. Decreased activity of 
voltage-gated K+ channel (Kv) leading to opening of voltage dependent Ca2+ channels 
(VDCC), 2. Activation of receptors (R), such as G-protein coupled receptors leading to the 
production of second messengers such as diacylglycerol (DAG) and inositol 1,4,5 
triphosphate (IP3), which mobilizes intracellular Ca2+, 3. Activation of receptor operated 
Ca2+ channels (ROC), 4. Opening of store-operated Ca2+ channels (SOC) by store depletion 
inducing Ca2+ mobilization from the sarcoplasmic reticulum (SR). Ca2+ binds to 
Calmomodulin (CaM), and the Ca2+/CaM complex activates myosin light chain kinase, 
phosphorylating the myosin light chain (MLC). This leads to crossbridge formation with 
actin filaments. The Ca2+/CaM complex also activates steps in the cell cycle propelling 
quiescent cells into mitosis (M) and cellular proliferation (+). The end result is 
vasoconstriction, smooth muscle proliferation and vascular remodelling leading to 
sustained elevations in pulmonary vascular resistance. Reprinted from Mandegar et al. 
(2004) with permission from Elsevier. 
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Testing acute vasodilator responses using short-acting agents such as intravenous adenosine 
and prostacyclin, or inhaled nitric oxide, should be undertaken in a systematic and careful 
manner. A positive vasoreactive response is defined as a reduction of MPAP mean PAP ≥10 
mmHg to reach a MPAP mean PAP <40 mm Hg with an increased or unchanged CO (Galie 
et al., 1995). While the RHC has clear advantages over ED for precise PAP, Sv02 and minute-
to-minute monitoring, it carries the disadvantage of being invasive and having limited 
ability to assess other relevant parameters such as RV function and size, left heart function 
and the presence of confounding pathologies like intercardiac shunts and significant 
valvular dysfunction. 
3.1.2 Doppler echocardiography 
Doppler echocardiographic monitoring of PAP began over 30 years ago when Hatle and 
colleagues applied Doppler ultrasound to calculate the time difference between PV closure 
and TV opening to estimate SPAP, basing the approach on earlier work by Burstin (Burstin, 
1967; Hatle et al., 1981). 
Not only is PAP obtainable noninvasively in the great majority of patients, but important 
associated right and left heart evaluations can be made and repeated when desired. An 
example would be where the PHT is secondary to pulmonary embolic disease and 
assessment of right heart structure and function to evaluate chronicity can be undertaken. 
The presence of significant RV wall hypertrophy indicates longstanding pathology; 
alternatively in the setting of acute PE the SPAP is unlikely to rise beyond 40 mm Hg 
(McIntyre & Sasahara, 1971;  Fisher et al., 2009). Guidelines recommend the subcostal (SC) 4- 
chamber view for measurements of RV wall thickness, which correlates with RV systolic 
pressure (Lang et al., 2005). 
Parameters measured directly or indirectly in PHT by ED include CVP/RAP, SPAP, DPAP, 
MPAP, RV systolic function, CO, and LAP. 
3.1.2.1 Right atrial pressure 
The calculation of this specific parameter using echocardiography has been established in 
haemodynamically stable, supine, spontaneously ventilated patients for many years using 
IVC diameter (D) changes, determined from the SC view, throughout the respiratory cycle 
(Brennan et al., 2007). A large IVC diameter (>21mm) with <35% collapsibility index 
(Dexpiration–Dinspiration/D inspiration X 100%) gives an RAP of 10-20 mmHg, 35-50% an RAP 10-15 
mm Hg, >55% an RAP 0-10 mm Hg. A smaller IVC ( <21mm) with a collapsibility index of 
35-55% gives a RAP 0-10 mm Hg, >55% 0-5 mm Hg. Unfortunately the relationship doesn’t 
hold for critically ill positive pressure ventilated patients when attempting to obtain a static 
RAP measurement. It does have value in determining fluid responsiveness in patients on 
controlled ventilation using the Distensibility Index or IVC variability index, but for the 
purposes of calculating a PAP a static measurement is required (Barbier et al., 2004; Feissel 
et al., 2004). Since many of these patients will have a central line in-situ it is recommended 
that the invasively obtained CVP be added to the ED derived RV-RA gradients.  
3.1.2.2 Pulmonary artery pressures 
(i) Systolic pulmonary artery pressure (SPAP) 
The tricuspid regurgitant (TR) jet method is the most commonly used method in clinical 
practice. It is operator dependent and this factor alone could explain the modest sensitivity 
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and specificity identified in a recent metanalysis (Janda et al., 2011). The preferred approach 
is to apply the continuous wave spectral Doppler across the tricuspid valve from either the 
apical 4 chamber (A4C) and/or parasternal short axis (PSAX) view, with careful attention to 
the angle of insonation to obtain the maximal regurgitant velocity. The modified Bernoulli 
equation is applied to calculate the RV-RA gradient, with subsequent addition of the RAP to 
calculate the SPAP. If an adequate TR jet is obtained the correlation with RHC-obtained 
SPAP measurements is very good (Janda et al., 2011). An experienced operator will take 
time to optimize the Doppler signal, especially when confounding factors such as minimal 
TR is present, the jet is eccentric, or there is poor coaptation of the tricuspid valve leaflets 
resulting in a broad turbulent jet. 
Diagnosis in the absence of tricuspid regurgitation: Nepean Index 
Using a combination of tissue Doppler velocity (TDI) of the lateral tricuspid annulus and the 
RV enddiastolic diameter (RVD), the ratio of RVD/Tpeak (whereTpeak=duration of TDI from 
the start of isovolumic contraction to peak systole) of > 22 cm/sec, predicted the presence of 
PHT, diagnosed as SPAP > 35 mm Hg, with 80% sensitivity and 83% specificity in patients 
with or without RV dysfunction (McLean et al., 2007).  
(ii) Mean pressure  
The diagnosis of pulmonary hypertension is based on the MPAP as measured by high-
fidelity RHC measurements where the MPAP is measured as the area under the pressure 
curve divided by the pulse interval (Badesch et al., 2009; McGoon et al., 2004). 
In clinical practice a flotation pulmonary artery catheter is generally utilized, which estimates 
the MPAP by the formula MPAP= 2/3DPAP+ 1/3SPAP. An extension therefore is to calculate 
the MPAP in a similar fashion utilizing ED derived SPAP and DPAP. Interestingly, further 
analysis indicates that SPAP is responsible for 98% of MPAP variability and therefore the use 
of the single parameter SPAP should be sufficient to accurately measure MPAP (Chemla et al., 
2009). In investigating 2 separate formulae, the Chemla and Syyed formulae, where only the 
SPAP and not the DPAP is used, Aduen and colleagues demonstrated similar accuracy and 
precision to RHC-obtained measurements by ED derived measurements, indicating they were 
suitable for clinical use (Aduen et al., 2011)30. 
Chemla formula:  MPAP  = 0.61 x SPAP + 2 mm Hg 
Syyed formula:  MPAP = 0.65 x SPAP + 0.55 mm Hg 
It has also been shown that the relationship between SPAP and MPAP remains linear during 
activity and change in posture (Syyed et al., 2008).  
(iii) Pulmonary artery diastolic pressure 
DPAP can be estimated using the pulmonary regurgitant jet. The velocity at end diastole is 
calculated and the modified Bernoulli equation is used.  
eg.        DPAP  = 4 x   (pulmonary regurgitant end diastolic velocity )2  + RAP 
3.1.2.3 Cardiac output 
This parameter can be obtained using the Simpsons Method from analysis of the left 
ventricular dimensions in the A4C and A2C views. Measurement of both left ventricular 
end diastolic and end systolic volumes is undertaken. The ultrasound machine has inbuilt 
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software that utilizes division into multiple discs and a resultant summation in the overall 
volume leading to a simple method of calculating CO. This along with the left ventricular 
outflow tract (LVOT) Doppler method of calculating the cardiac output has been validated 
in the critically ill population (McLean et al., 1997). 
The latter method is more reliable but does require more experience because continuous 
wave (CW) Doppler is involved. The more experienced operator should adopt the latter 
approach. The right ventricular outflow can also used in preference to the LVOT if desired.  
3.1.2.4 RV systolic function 
Assessment of right ventricular contraction on a regular basis in a critically ill patient with 
PHT is absolutely essential. Prognosis depends on the ability of the RV to adapt to elevated 
PAP, and being a thinned wall chamber its ability to adapt to systolic demands is limited. 
RV contractility can be monitored subjectively or objectively.  
The subjective assessment of RV contraction relies upon both chamber sizes and visual 
‘eyeballing ‘ of the RV free wall. Dilatation of the RV is a guide to pulmonary pressure 
and/or fluid status. The relative area or volume of the RV to the LV as seen in the A4C view 
using transthoracic echocardiography or mid-oesphageal view using transoesophageal 
echocardiography should be <0.6, with a ratio of >1.0 indicating marked RV dilatation and 
0.6-1.0 moderate dilatation. Paradoxical septal motion, usually best seen in the parasternal 
short axis view, adds to the evaluation with abnormal systolic motion indicating pressure 
overload and abnormal diastolic motion indicating RV fluid overload. The free wall of the 
RV is best viewed in the SC and A4C views although may be visualized in other views. 
Particular attention to RV wall thickness should be taken to assist in determining the 
chronicity of the PHT. 
A number of parameters have been used in the evaluation of RV systolic function but most 
studies have demonstrated the clinical value of Right ventricular Myocardial performance 
index (RV MPI), tricuspid annulus plane systolic excursion (TAPSE), fractional area change 
(FAC) and S’ of the tricuspid annulus (Rudski et al., 2010).  
i) Right Ventricular Myocardial Performance Index  
The Myocardial Performance Index or ‘Tei  Index’ was initially validated as a index of global 
left ve ntricular function but became adapted to the right heart (Karnati et al., 2008). RV MPI 
requires PW or CW Doppler recordings of the TV inflow and RV outflow. RV MPI is 
calculated from the isovolumic contraction time, isovolumic relaxation time and ejection 
time. A RV MPI >0.40 indicates global RV dysfunction. If tissue Doppler of the lateral 
tricuspid annulus is used, then global RV dysfunction is present if the RV MPI >0.55. The 
latter avoids errors related to variability in heart rate although both are less accurate with 
increasing RA pressures because of a decrease in the IVRT. 
ii) TAPSE 
The tricuspid annulus plane systolic excursion (TAPSE), otherwise known as the Tricuspid 
Annulus Displacement (TAD), is a parameter obtained by placing the M-mode cursor over 
the lateral tricuspid annulus. Although only one small part of RV motion is evaluated, this 
single simple measurement has been demonstrated to be a relatively reliable guide in both 
diagnostic and prognostic studies. A TAPSE of 16 mm or less implies RV contractile 
impairment (Forfia et al., 2006; Rudski et al., 2010). 
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iii) Right Ventricular Fractional Area Change 
RV FAC is defined as (enddiastolic area –endsystolic area)/enddiastolic area x 100 and 
correlates with MRI evaluation of RV systolic function (Anavekar et al., 2007). 
Measurements of FAC are taken in the A4C view with the RV cavity area traced from the 
tricuspid annulus along the free wall and back down the ventricular septum, in both systole 
and diastole. A normal RV FAC is >35%. 
iv) S’ obtained by Tissue Doppler Imaging 
From the A4C view the tricuspid annulus and basal free wall segments of the right ventricle 
can be assessed by either pulsed tissue Doppler or colour tissue Doppler to measure 
longitudinal velocity excursion. The S’ velocity of the basal free wall measured by pulsed 
wave Doppler is the recommended value to measure (Rudski et al., 2010). Population 
studies give normal values of 15 cm/sec at the annulus and basal free wall. The lower limit 
of normal can be taken as 10 cm/sec (Lindqvist et al., 2005). 
This is a simple and reproducible parameter with a S’ <10 cm/s indicating abnormal RV 
systolic function in adult patients. 
3.1.2.5 Left atrial pressure 
Either direct measurement of the LAP, or a surrogate, is essential when monitoring PHT. 
The contribution of left heart dysfunction, or lack thereof, needs to be established. Also, 
over time an elevated PAP needs to be continually assessed, particularly in a patient with 
underlying PHT who is failing to improve and where LV dysfunction or elevated LAP 
develops during the ICU stay. A subjective view of the left heart may identify contractile 
dysfunction or significant left ventricular wall hypertrophy suggesting the presence of 
clinically relevant diastolic dysfunction. A number of methods including analysis of the 
mitral inflow wave form, pulmonary venous waveform, and M-Mode colour Doppler 
across the mitral inflow have been used historically for diastolic assessment, as a guide to 
elevated LAP. However, today the application of TDI makes the situation easier, 
particularly when combined with a dilated left atrium. The E/E’ is of proven value in 
identifying elevated left atrial pressure, particularly when combined with a dilated left 
atrium. 
3.2 Periodicity of measurements 
The third component of the monitoring triad is that of periodicity and this may dictate 
which technique should be chosen in a particular patient. If daily assessment of the 
selected parameters is sought then ED in the majority of patients is sufficient. Where 
minute-to-minute monitoring is required and the parameters are limited to PAP and CO 
then the RHC should be considered. Where parameters are to be measured every few 
hours than the choice may depend on the availability and expertise present in the ICU. A 
word of caution is that if the RHC is chosen, then an ED should also be undertaken at 
some stage allowing for a better overall assessment of cardiovascular status. Conversely if 
very precise PAP measurements are required then a RHC should be chosen. Table 2 
summarizes the main characteristics, advantages and disadvantages of the two modes of 
monitoring. 
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 Pulmonary Artery 
Catheter 
Echo Doppler 
Ease of use Requires training Requires training 
Portability No Yes 
User 
dependence 
No, but data interpretation 
requires training 
Yes, for data acquisition and 
interpretation 
Continuous 
measurement Yes No 
Invasive Yes No 
CO 
measurement Yes Yes 
Pressure 
measurements Direct Indirect, pressure are calculated 
Evaluation of 
RV function No Yes 
Table 2. Characteristics of PAC and ED monitoring 
4. Heart-lung interactions and mechanical ventilation 
Mechanical interactions between the respiratory and circulatory systems are produced by 
changes in the intrathoracic pressure (ITP) and changes in the lung volume. The institution 
of positive pressure ventilation (PPV) profoundly affects both ITP and lung volumes. To add 
further complexity, these effects may vary considerably between the healthy state and 
during disease, particularly in acute respiratory failure (ALI/ARDS). Pulmonary 
hypertension (PHT) is a notable feature of ALI/ARDS. 
The heart and lungs are anatomically linked by their shared position in the thorax, with the 
vascular compartments acting like pressure chambers within a pressure chamber during 
PPV. This has important implications for the heart-lung interactions. The serial vascular 
arrangement of the heart and lungs means that any changes of right ventricular (RV) 
function will change pulmonary perfusion that in turn will change left ventricular (LV) 
function (Figure 3).  
The venous return determines RV and LV output that must remain equal albeit small 
variations occur from heartbeat to heartbeat. Furthermore, the right and left ventricles of the 
heart are linked to each other by common myocardial tissue, the septal wall and the 
enclosure in the fibrous, non-compliant pericardial sac. These features result in ventricular 
interdependence, i.e. forces are transmitted from one ventricle to the other (Bove & 
Santamore, 1981). Diastolic ventricular interdependence means that increased volume-
pressure in one ventricle will shift the compliance curve of the other ventricle to the left and 
upward (Weber et al., 1981). Diastolic interdependence is present during physiological 
conditions and is accentuated by PPV. Conditions involving the pericardium, e.g. cardiac 
tamponade and constrictive pericarditis, further accentuate diastolic ventricular 
interdependence. Systolic ventricular interdependence occurs as a physiological 
phenomenon and experimental data suggest that 20-40% of right ventricular systolic 
pressure result from left ventricular contraction (Damiano et al., 1991). The greater part of 
ventricular interdependence occurs through the septum although the ventricular free wall is 
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also involved. Conditions that decrease the relative compliance of the septum, such as 
volume overload, increase ventricular interdependence as does increased stiffening of the 
right ventricle, for example by PHT (Santamore & Dell’Italia, 1998). 
 
Fig. 3. Heart-lung interactions - effects of mechanical ventilation. Increased transpulmonary 
pressure due to positive pressure ventilation increases RV afterload, whilst RV preload is 
decreased due to the decreased venous return. During the inspiratory phase, LV preload is 
transiently increased due to a ‘squeezing’ effect from pulmonary vasculature into the left 
atrium. Ultimately however, the decrease in RV filling leads to decreased LV filling and 
output. TP=transpulmonary pressure=alveolar-pleural pressure. Adapted from Michard  & 
Teboul (2000). 
The RV preload is determined by the venous return, governed by the pressure gradient 
between mean systemic pressure and right atrial pressure, as well as caval size and 
collapsibility. Increased ITP generated by PPV may thus reduce venous return by decreasing 
the mean systemic to right atrial pressure gradient and by compressing the cavae, limiting 
flow (Michard & Teboul, 2000; Shekerdemian & Bohn, 1999). These effects can be offset by 
intravascular volume loading to increase mean systemic pressure, by increasing the 
extrathoracic pressure on large vessels, e.g. increasing intraabdominal pressure to increase 
mean systemic pressure, or by increasing venous vascular tone (through sympathetic 
activation or drugs). The classical effects of PEEP originally described by the two Nobel 
laureates Cournand and Richards (Cournand et al., 1948) are clinically not as prominent 
probably related to increased intraabdominal pressure by the diaphragmatic descent 
produced by PEEP and by sympathetic activation. Normally RV diastolic compliance is so 
high that RAP changes largely reflects changes in pericardial pressure rather than RV filling 
per se. Hence RAP is a poor indicator of RV end-diastolic filling. In patients with decreased 
RV compliance, such as in PHT, the dissociation between RAP and RV end-diastolic filling 
is lost. 
LV function is influenced by PPV via the effects on RV function, thus governing LV filling, 
and by reduction of thoracic aortic transmural pressure leading to increased compliance and 
hence reduced LV afterload. Reduction of LV transmural pressure, and as a result LV mural 
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tension, decreases oxygen consumption and forms the rationale for using PPV in patients 
with acute heart failure (Räsänen et al., 1985).  
The ITP and airway pressures influence vascular pressures, but the extent and regional 
distribution of this effect may differ considerably in ALI/ARDS due to the uneven 
distribution of lung volume and alveolar pressure. Poorly compliant lungs, characteristic of 
ALI/ARDS, generally “protect” the vasculature from high airway pressures, meaning that 
PHT in this setting might not be as closely related to airway pressures as seen in less 
diseased lungs (Jardin et al., 1985). More precisely, the ITP significantly influences 
transmural pressure, i.e. the intravascular to ITP difference. This needs to be considered 
when assessing cardiac filling pressures as well as pulmonary vascular resistance (PVR). 
Increased ITP during PPV will decrease RV and LV filling in the setting of unchanged 
chamber pressures, since the transmural pressure decreases, even if RV and LV functional 
characteristics remain unchanged. The PVR is a complex variable, consisting of Poiseulle 
and Starling resistors, the details of which are beyond the context of the present review, and 
should not be viewed in the simplistic “Ohmic” manner typically applied to the systemic 
circulation (Versprille, 1984). The pulmonary blood is the sum of RV output and shunt flow 
from bronchial arteries to the pulmonary artery. The latter might increase significantly in 
RV failure and PHT to maintain pulmonary perfusion. Pulmonary vascular resistance is 
equally divided between pulmonary arteries/arterioles, capillaries and venules/veins. 
Active neurogenic and humoral vasoconstriction plays a minor role to control resistance and 
as a consequence regional distribution of pulmonary flow depends on other factors 
including gravity and hypoxic pulmonary vasoconstriction. 
Oesophageal pressure can be used to estimate the ITP, and thus to work out vascular 
transmural pressures. Similarly, the transpulmonary pressure can be assessed, determining 
the stretch of the lungs. The caveat of airway pressure not being uniformly transmitted onto 
intrathoracic structures, including the oesphagus, must be kept in mind (Jardin et al., 1985). 
Mechanical ventilation has complex effects on (PVR). In respiratory failure PPV can reduce 
PVR by increasing oxygenation above above 60 mm Hg to alleviate hypoxic pulmonary 
vasoconstriction (HPV). Furthermore, sympathetic outflow can be diminished by reducing 
work of breathing and by increasing alveolar ventilation to attenuate respiratory acidosis. 
The relationship between lung volume and PVR is U-shaped with increased PVR occuring 
at low lung volumes (due to increased resistance in extra-alveolar vessels and alveolar 
collapse increasing HPV) and at high lung volumes (due to hyperinflation and increased 
alveolar pressure compressing alveolar vessels) (Whittenberger et al., 1960). PVR is lowest at 
FRC that is typically reduced in ALI. The effects of PEEP on PVR are highly dependent on 
the intravascular volume status. Increased intravascular filling mitigates the potential of 
raised ITP to transfer lung areas from West zone 3 to zones 1 or 2 (Fourgéres et al., 2010). 
Ventilator settings for patients with PHT with incipient or manifest RV failure should be 
tailored to minimize inspiratory swings in ITP, i.e. small tidal volumes (6 ml/kg) delivered 
with a slow rise to peak inspiratory pressure. The expiratory drop in ITP should be rapid 
with the expiratory time set to minimize intrinsic PEEP, usually meaning expiratory time 
should at least equal the inspiratory time. 
Severely increased PVR either acutely or added onto pre-existing PHT, for example by 
mechanical ventilation, can precipitate acute cor pulmonale with RV distension, septal 
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flattening and leftward displacement with impaired LV filling and rapid haemodynamic 
deterioration. Fluid administration in this setting can further worsen RV failure and the use 
of extracorporeal circulation might be the only therapeutic option for the acutely pressure- 
and volume-overloaded RV (Höhn et al., 1999). 
5. Current therapeutic strategies 
Pharmacological management of right heart failure and pulmonary vascular disease in the 
intensive care is dependent on its aetiology. While pulmonary hypertension may be due to 
left heart and/or underlying lung disease, its ultimate effects on the right heart are 
considered to be particularly deleterious. There are many components that can be related to 
the clinical syndrome of right heart failure seen in the critical care patient.  This includes 
hypoxic pulmonary vasoconstriction, microvascular thromboses, increase or decrease of the 
permeability of the pulmonary vasculature and endothelial dysfunction.  Further, changes 
in the lungs may precipitate right ventricular failure.  RV failure may be primarily be related 
to RV function – for example due to ischemia of the right ventricle, volume overload or 
sepsis – or be secondary to LV failure. The management protocol of right ventricular 
dysfunction is dependent on the aetiology of the disease process, and these must be 
addressed prior to the isolated management of RV dysfunction. We will concentrate on 
specific management of RV dysfunction from this point onwards.  
Management of RV dysfunction can be separated into surgical and pharmacological. 
5.1 Surgical management 
5.1.1 Intra Aortic Balloon Pump (IABP) 
IABPs can support LV dysfunction but is of limited use in RV dysfunction.  This is due to 
the differences in timing of coronary arterial filling of left and right coronary arteries. As the 
IABP inflates during diastole , it substantially augments left coronary filling. However the 
right coronary artery fills throughout systole and diastole, hence any diastolic augmentation 
of coronary filling is relatively small in the RV.  Equally, IABP decreases the afterload for the 
left ventricle, but this does not affect right ventricular afterload. Right coronary perfusion is 
affected by the gradient between the intra ventricular pressure in the right ventricle and the 
coronary perfusion pressure – so the RV pressure must also be optimized, as too high an RV 
pressure will induce RV ischaemia. Pulmonary arterial pressures are raised by positive 
pressure ventilation hence all efforts should be made to move as rapidly as possible to 
negative pressure ventilation.  Many centers will tracheostomise patients for this process. 
Equally if there is a risk of hypoxic pulmonary vasoconstriction, optimisation and 
maintaining a PO2 >100mHg may reduce any pulmonary arterial vasoconstriction and 
hence decrease RV afterload.  
5.1.2 Assist devices 
Mechanical assist devices have been developed specifically with left ventricular support in 
mind. First generation ventricular assist devices such as Thoratec PVAD™ (Pleasanton, 
California, USA) and Abiomed BV5000™ (Massachusetts, USA)  can be used in the 
biventricular setting.  However this limits mobilization of the patient.  A short-term device 
such as Levotronix™ (Massachusetts, USA) , or extracorporeal membrane oxygenation 
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(ECMO) can improve RV dysfunction in the acute setting but again limits the mobility of the 
patient and the ability to move from intensive care. In the setting of long term mechanical 
RV support, work is ongoing regarding the development of an implantable biventricular 
devices/total artificial heart , and using two rotary pumps in series, (Timms et al., 2008) - 
one for left and one for right ventricular support (Gregory et al., 2011). This necessitates 
either changing pump speeds or crimping the outflow of the VAD placed in the right heart 
to decrease pressures consistent with pulmonary arterial pressure (Timms et al., 2011). This 
would only be used in the chronic setting which is refractory to medical management. 
Whilst laboratory research has not been completed, some centres have already used this 
technique clinically (Strueber et al., 2010). 
5.2 Pharmacological management 
The pharmacological management of right ventricular dysfunction should aim at: 
1. Prevention of right ventricular ischemia; 
2. Improving right ventricular cardiac output;  
3. Reducing pulmonary vascular resistance to a greater degree than systemic vascular 
resistance.   
5.2.1 Prevention of right ventricular ischemia 
Right ventricular ischaemia is clearly associated with increased mortality (Jacobs AK et al., 
2003). Since the right coronary artery is filled through both systole and diastole with the 
majority of flow occurring through systole, the aortic root pressure is a key determinant of 
right coronary filling.  Adequate systolic pressure is therefore required to optimize right 
ventricular oxygenation and this may necessitate vasopressor support. Vasopressors should 
be used carefully since they may increase left ventricular afterload, resulting in a shift of the 
intraventricular septum towards the right ventricle and reducing its output (see Section 4). 
Vasopressors which increase systemic systolic pressure may also increase pulmonary 
vascular pressure and the resistance which the failing right ventricle has to oppose. 
Therefore there is a trade-off between increasing right coronary perfusion pressures and 
increasing left and right ventricular afterload. Phenylephrine is well recognised to worsen 
right ventricular function.  The data for Adrenaline and Noradrenaline are less clear. 
Increased, unchanged or decreased pulmonary vascular resistance (PVR) have been 
documented (Ghighone et al., 1984; Hirsch et al., 1991; Le Tulzo et al., 1997) 
Vasopressin has some attributes suggesting it may be useful in patients with pulmonary 
vascular disease and RV dysfunction. In conscious animal models, vasopressin induces 
reversed drug induced vasoconstriction and induced pulmonary vasodilation (Trempy et 
al., 1994). In an ex-vivo model Evora et al describe how Vasopressin induces pulmonary 
vasodilatation due to a release of nitric oxide whilst simultaneously inducing systemic 
vasoconstriction. (Evora et al., 1993). The data in humans is much less clear.  When 
Vasopressin and Noradrenalin were used to mitigate the hypotension associated with 
Milrinone Jeon et al noted that Vasopressin induced differential effects in the systemic and 
pulmonary vasculature, with a beneficial reduction in the PVR/SVR ratio following 
vasopressin only (Jeon et al., 2006). As has been described, maintenance of systemic pressure 
to optimize right coronary filling, with minimal or no simultaneous increase in PVR are 
ideal attributes in patients with the failing right ventricle. 
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Hence, data is clear that Phenylephrine seems to be deleterious in the face of right 
ventricular dysfunction; Noradrenalin improves coronary filling and may improve cardiac 
output, while animal and limited human data suggest that Vasopressin increases systemic 
pressure with minimal adverse effects on the pulmonary circulation.   
5.2.2 Improving right ventricular cardiac output 
Vasopressors may improve cardiac output through increasing coronary filling.  However, 
there is more data to support the use of inotropic agents such as Levosimendan, 
Dobutamine, Milrinone and Adrenaline in right ventricular failure although Noradrenaline 
should not be entirely dismissed.  Inodilators such as Dobutamine have a number of 
properties that make it ideal in the face of pressure overload of the RV. In causing systemic 
vasodilation it reduces the preload to the right ventricle and improves right ventricular 
contractility with minimal effect on pulmonary vascular resistance.  (Pagnamenta et al., 
2003). Some data support the use of Levosimendan in the similar situation, where it 
increases in cardiac output by increasing right ventricular contractility, decreasing 
pulmonary vascular resistance and improving RV-PA coupling (Kerbaul et al., 2006). Of 
note, there are few studies of Levosimendan for the treatment of sepsis-induced 
cardiomyopathy and pulmonary hypertension. 
The phosphodiesterase-3 (PDE3) inhibitors improve cardiac output through improved 
contractility and reduction in both systemic and pulmonary arterial pressure. Milrinone is 
the most commonly used drug of this family at present.  However in patients with severe 
right ventricular dysfunction an associated renal failure, drug accumulation may be a 
difficulty. There is minimal data on its clearance during continuous renal replacement 
therapy.  Milrinone is most commonly administered intravenously but there are interesting 
reports of substantial benefits using the inhalational route.  This is presumed to be due to a 
direct delivery to the pulmonary circulation with avoidance of systemic effects such as 
hypotension.  A number of studies confirm the reduction in pulmonary arterial pressure 
and pulmonary artery resistance with maintenance of systemic pressure, especially in 
combination with vasopressors (Jeon et al., 2006). An additional benefit is an improvement 
of PaO2/FiO2 ratio, due to optimization of ventilation/perfusion by the selective action on 
Milrinone delivery to only aerated alveoli. This improvement in oxygenation may further 
assist the right ventricle and decrease pulmonary arterial pressure by attenuating hypoxic 
pulmonary vasoconstriction (Wang et al., 2009). 
5.2.3 Pulmonary vasodilatation  
Increased pulmonary vascular resistance is often associated with, and worsens right 
ventricular dysfunction.  Therefore another strategy for improving right ventricular function 
is to reduce pulmonary vascular resistance, thereby decreasing RV afterload. Nitric oxide 
(NO) can be easily administered and measured, and reduces pulmonary vascular resistance.  
It is commonly used after mitral valve and congenital heart surgery where right ventricular 
failure is a common occurence.  Contrary to the evidence in ARDS where NO has no 
beneficial affect on clinical outcome, it is clear that NO reduces pulmonary vascular 
resistance in patients with idiopathic pulmonary arterial hypertension, and has a proven 
role in this situation.  Prostacyclin may be nebulised or given intravenously.  It is derived 
from pulmonary endothelial cells, and is used in the stable chronic pulmonary hypertensive 
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patients in an intravenous form with good effect (Benedict et al., 2007). However in the 
critically ill population, significant systemic vasodilation limits the usefulness of 
intravenously administered Prostacyclin.  Moreover, its effect on platelet aggregation 
precludes its use in patients at risk of bleeding.  Nebulised Prostacyclin however avoids 
these risks and has a very short half-life. It may be given up to three hourly, and can be 
useful for extubating patients requiring NO, who frequently become unstable when 
removing the last 1-2 parts per million. Nebulised drugs such as NO, Prostacyclin and 
Milrinone will not only reduce pulmonary vascular resistance but also optimize the 
ventilation-perfusion ratio since the drug is only delivered to aerated alveoli. Iloprost is an 
analogue of Prostacyclin with a much longer half-life of thirty minutes and a clinical activity 
of approximately sixty minutes.  This makes it more practical to use in a critical care 
environment.  These inhaled agents may be combined for improve synergistic affect.  
Research has been conducted investigating synergisitic combinations of Sildenafil and NO, 
Iloprost and NO, nebulised Milrinone and Prostacyclin, and Iloprost and Sildenafil, as well 
as the use of Sildenafil to allow safe weaning from NO (Huang J et al., 2011; Kumar et al., 
2010; Lakshminrusimha et al., 2009; Lee et al., 2008; Winterhalter et al., 2010).   
Oral Sildenafil has been used for the treatment of pulmonary hypertension in the critically 
ill for some time, and more recently has become available as an intravenous form.  This 
phosphodiesterase type 5 inhibitor substantially decreases the pulmonary vascular 
resistance although a smaller reduction in systemic pressure also occurs. There is limited 
experience with intravenous sildenafil but this preparation would potentially be beneficial 
in patients who have inadequate gastric absorption due to splanchnic venous hypertension, 
a condition seen very frequently seen in patients with right ventricular dysfunction (Abrams 
et al., 2000; Barst et al., 1996; Prasad et al., 2000; Zhao et al., 2001)   
 
Goal Drug Route Mechanism
Prevention of 
RV 
ischaemia 
Noradrenaline i.v. Increases systemic (=aortic root) 
pressure  improves right coronary 
arterial filling  
Adrenaline i.v.
Vasopressin i.v.
Improve RV 
output 
Dobutamine i.v.
Increases RV contractility 
Inodilation  reduces PVR  
decreases RV afterload 
Adrenaline i.v.
Levosimendan i.v.
PDE3 inhibitors eg. 
Milrinone
i.v., 
inhaled
Pulmonary 
vasodilation 
Nitric Oxide inhaled
Dilates pulmonary vascular bed  
reduces PVR  decreases RV 
afterload 
Improves V/Q matching 
Prostacyclin i.v., inhaled
Iloprost i.v.
Milrinone i.v., inhaled
PDE5 inhibitors 
eg. Sildenafil i.v., p.o. 
ET-receptor 
antagonists  
eg. Bosentan
p.o. 
Table 3. Medical management of pulmonary hypertension 
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Endothelin antagonists such as Bosentan have minimal role in the critical care patient 
population as they take between three and six months to cause any effect.  If they have been 
administered chronically to a patient, they should not be ceased acutely in ICU as this may 
induce rebound pulmonary hypertensive crisis. Care must be taken specifically with liver 
dysfunction.  
Finally, some inotropic agents such as Milrinone, Dobutamine, Adrenaline and 
Levosimendan may have dual actions of improving cardiac output as well as reducing 
pulmonary vascular resistance (Chew et al., 2008; Jeon et al., 2006; Kerbaul et al., 2006; Le 
Tulza et al., 1997; Pagnamenta et al., 2003; Price et al., 2010;). A clinically useful systematic 
review with GRADE recommendations for the management of pulmonary vascular and 
right ventricular dysfunction may be found in Price et al (2010). 
Regardless of drug and mechanical assistance to the patient with the failing right ventricle, 
there must be close and effective observation to assess response to therapy. Similarly, whilst 
volume challenges have a role in right ventricular failure, these should be small, with 
repeated assessment of adequacy of response, due to the impaired Frank-Starling 
mechanism. 
6. Conclusion 
Pulmonary hypertension occurs commonly in the critically ill population. The aetiology of 
this disease is varied and it is often associated with right ventricular failure. The presence of 
the latter increases mortality therefore treatment strategies for pulmonary hypertension also 
involve improving right ventricular function. The mainstay of therapy is pharmacological, 
and is aimed at reducing pulmonary vascular resistance, improving ventilation-perfusion 
matching and improving RV function. Commonly used therapies in critical care such as 
fluid loading, mechanical ventilation and vasopressor therapy have a place but must be 
used judiciously since they may worsen pulmonary vascular resistance and right ventricular 
function. Monitoring is essential in this population and a combination of right heart 
catheterization and Echo Doppler methods may be used. This paper provides an up-to-date 
review on the pathophysiology, monitoring and clinical management of pulmonary 
hypertension in critically ill adults. 
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